Vandy Black

Vandy Black has a strong background in the field of medical and clinical development. They have held various roles throughout their career, starting with a position as a Pediatric Hematology-Oncology Fellow at The University of Alabama at Birmingham from 2006 to 2009. Following this, they worked as an Assistant Professor of Pediatric Hematology at Johns Hopkins School of Medicine from 2009 to 2012. They then joined Our Lady of the Lake Regional Medical Center as a Pediatric Hematologist-Oncologist from 2012 to 2015. Vandy Black furthered their career by becoming an Associate Professor and Medical Director of the Pediatric Sickle Cell Disease Program at the University of Florida from 2015 to 2021. During this time, they also served as the Pediatric Hematology and Oncology Fellowship Program Director. In 2021, Vandy Black joined FORMA Therapeutics, Inc. as a Medical Director of Clinical Development until 2022. They then transitioned to Novo Nordisk, where they served as an International Medical Director of Clinical Development from 2022 to 2023. Currently, Vandy Black is a Senior Medical Director of Early Clinical Development at Deciphera Pharmaceuticals, starting in 2023. Overall, Vandy Black's work experience demonstrates their expertise in pediatric hematology-oncology and their significant contributions to clinical care, research, and medical education.

Vandy Black has a Bachelor of Science (BS) degree in Biology from The University of Alabama, which was obtained in 1999. They then attended the University of Alabama School of Medicine and earned a Doctor of Medicine (MD) degree in 2003. Later, Vandy pursued a Master of Science (M.Sc.) in Clinical Investigation from the Johns Hopkins Bloomberg School of Public Health, completed by 2014. Additionally, they have a certification in Pediatrics and Pediatric Hematology-Oncology from the American Board of Pediatrics. The specific month and year of obtaining this certification are not provided.